Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 2/20 | 0.51 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | TACR2 | P21452 | 1/20 | 0.43 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.43 |
| ▸ | MTOR | P42345 | 1/20 | 0.43 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.42 |
| ▸ | HRAS | P01112 | 2/20 | 0.40 |
| ▸ | SLC5A2 | P31639 | 2/20 | 0.40 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
| ▸ | GJB2 | P29033 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6659183 | 1.00 | SLC6A2 (0.51) | SLC6A2PDE4DTSHRCYP2C19TACR2 | |
| SCHEMBL969972 | 1.00 | SLC6A2 (0.51) | SLC6A2PDE4DTSHRCYP2C19TACR2 | |
| SCHEMBL969974 | 1.00 | SLC6A2 (0.51) | SLC6A2PDE4DTSHRCYP2C19TACR2 | |
| SCHEMBL8960128 | 0.95 | SLC6A2 (0.52) | SLC6A2PDE4DTSHRCYP2C19TACR2 | |
| SCHEMBL8960525 | 0.95 | SLC6A2 (0.52) | SLC6A2PDE4DTSHRCYP2C19TACR2 | |
| SCHEMBL8960125 | 0.95 | SLC6A2 (0.52) | SLC6A2PDE4DTSHRCYP2C19TACR2 | |
| SCHEMBL8960350 | 0.95 | SLC6A2 (0.52) | SLC6A2PDE4DTSHRCYP2C19TACR2 | |
| SCHEMBL8960222 | 0.95 | SLC6A2 (0.52) | SLC6A2PDE4DTSHRCYP2C19TACR2 | |
| SCHEMBL8960215 | 0.95 | SLC6A2 (0.52) | SLC6A2PDE4DTSHRCYP2C19TACR2 | |
| SCHEMBL6552387 | 0.92 | SLC6A2 (0.50) | SLC6A2PDE4DTSHRCYP2C19TACR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1165578-B1 | METHODS AND COMPOSITIONS FOR THE MANUFACTURE OF C-3' AND C-4' ANTHRACYCLINE ANTIBIOTICS | PRIEBE WALDEMAR (US) | 2012-02-22 | — | — | EP | disclosed |
| US-7557090-B2 | Anthracycline antibiotics and methods of treating cancer using the same | HOUSTON PHARMACEUTICALS, INC. (US) | 2009-07-07 | — | — | US | disclosed |
| US-20070037758-A1 | administering with a DNA damaging agent; modified alkyl-aromatic ring substitutions on the C-3' of the sugar moiety or alkyl-aromatic ring substitutions at the C-4' of the sugar; cytotoxicity; antitumor, anticarcinogenic agents; multidrug resistance; compounds act by intercalating with DNA | HOUSTON PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | US | disclosed |
| US-7109177-B2 | Methods and compositions for the manufacture of C-3′ and C-4′ anthracycline antibiotics | HOUSTON PHARMACEUTICALS, INC. (US) | 2006-09-19 | — | — | US | disclosed |
| US-6673907-B2 | NOVEL SUBSTITUTED TETRACYCLINES WITH MODIFIED ALKYL-AROMATIC RING SUBSTITUTIONS ON THE C-3' AND/OR C-4' OF THE SUGAR MOIETY; CYTOTOXICITY; ANTITUMOR, -CARCINOGENIC AGENTS; MULTIDRUG RESISTANCE | HOUSTON PHARMACEUTICALS, INC. | 2004-01-06 | — | — | US | disclosed |
| US-20020137694-A1 | Methods and compositions for the manufacture of C-3' and C-4' anthracycline antibiotics | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2002-09-26 | — | — | US | disclosed |
| EP-1165578-A4 | METHODS AND COMPOSITIONS FOR THE MANUFACTURE OF C-3' AND C-4' ANTHRACYCLINE ANTIBIOTICS | PRIEBE WALDEMAR (US) | 2002-08-28 | — | — | EP | disclosed |
| EP-1165578-A2 | METHODS AND COMPOSITIONS FOR THE MANUFACTURE OF C-3' AND C-4' ANTHRACYCLINE ANTIBIOTICS | Priebe, Waldemar (US) | 2002-01-02 | — | — | EP | disclosed |
| WO-2000056267-A2 | METHODS AND COMPOSITIONS FOR THE MANUFACTURE OF C-3' AND C-4' ANTHRACYCLINE ANTIBIOTICS | PRIEBE WALDEMAR (US) | 2000-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037758-A1 | administering with a DNA damaging agent; modified alkyl-aromatic ring substitutions on the C-3' of the sugar moiety or alkyl-aromatic ring substitutions at the C-4' of the sugar; cytotoxicity; antitumor, anticarcinogenic agents; multidrug resistance; compounds act by intercalating with DNA | PCNA, DDB1, TOP1 | SLC6A2 1868/4885PDE4D 3302/4885TSHR 3741/4885 |
| US-20020137694-A1 | Methods and compositions for the manufacture of C-3' and C-4' anthracycline antibiotics | HCCS, GALE, BCL3 | SLC6A2 3427/4885PDE4D 1329/4885TSHR 3680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.